Table 1.

Selected clinical studies targeting immune inflammatory pathways in myocardial infarction.

Trial	Conditions	Interventions	Outcomes	Ref.
ASSAIL-MI	First-time STEMI	Single dose of tocilizumab (IL-6R antibody) vs. placebo	Improved myocardial salvage with tocilizumab	NCT03004703 [125]
CLEAR-SYNERGY	STEMI treated with primary PCI	SYNERGY stent plus colchicine and spironolactone or placebo	Ongoing	NCT03048825
COVERT-MI	First STEMI treated with primary PCI	5-day administration of colchicine vs. placebo	Colchicine did not reduce infarct size	NCT03156816 [120]
LILACS	Stable CAD and ACS	Low-dose aldesleukin (recombinant IL-2)	This phase I/II trial showed safety and tolerability of aldesleukin	NCT03113773 [128]
RITA-MI	Acute anterior STEMI treated with primary PCI	Single intravenous injection of rituximab (anti-CD20 monoclonal antibody)	This phase I/IIa trial showed safety and tolerability of rituximab	NCT03072199 [129]
VCUART3	Acute STEMI	Anakinra (IL-1R antagonist) vs. placebo	Anakinra significantly reduced systemic inflammatory response	NCT01950299 [122]
VCUART4	Acute STEMI	Anakinra (IL-1R antagonist) vs. placebo	Not yet recruiting. Planned to assess how well anakinra can protect participants from developing heart failure	NCT05177822